The only news of consequence was that BAX and MNTA are already working on the third FoB compound. Moreover, Wheeler's hint about the identities of the three FoB compounds was helpful and solidified my predictions, as noted in #msg-78125123.
Further, it was helpful for Wheeler to mention that that the FDA review of MNTA's Copaxone ANDA is continuing without any known problems and that the FDA can issue a tentative approval at any time. Readers of this board already knew that, of course, but some investors and analysts might have thought the FDA review of the ANDA was on hold.
Market Data 
Markets 
AI
